Adeno-associated virus packaging vectors and methods of use thereof

By integrating an artificial intron into the AAV rep gene, the plasmid prevents abnormal packaging, ensuring the production of replication-deficient AAV particles, thus improving the efficiency and safety of AAV packaging.

CN119072543APending Publication Date: 2024-12-03JANSSEN RESEARCH & DEVELOPMENT LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380036106.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-25
Filing Date
2023-04-19
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing AAV packaging technologies face inefficiencies in efficiently packaging of the rep and cap genes into the rAAV capsid, leading to abnormal packaging and potential contamination by replication-competent AAV.

Method used

A plasmid is constructed with AAV2 replication genes and AAV5 capsid genes, incorporating an artificial intron into the rep gene to prevent abnormal packaging, using a 2 kb intron that makes the rep and cap coding regions too large for inclusion in the rAAV capsid.

Benefits of technology

The solution effectively prevents abnormal packaging and ensures the production of replication-deficient AAV particles, enhancing the purity and safety of the AAV packaging process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005099921820000151
    Figure BDA0005099921820000151
  • Figure BDA0005099921820000161
    Figure BDA0005099921820000161
  • Figure BDA0005099921820000171
    Figure BDA0005099921820000171
Patent Text Reader

Abstract

Provided herein are nucleic acid molecules comprising an artificial intron and a modified replication coding sequence. Also provided are vectors and cells comprising a nucleic acid molecule comprising an artificial intron and a modified replication coding sequence.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-references

[0002] This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application No. 63 / 334,455 filed on April 25, 2022 and U.S. Provisional Application No. 63 / 334,468 filed on April 25, 2022, each of which is incorporated by reference in its entirety. Technical Field

[0003] Disclosed herein are nucleic acid molecules comprising an artificial intron and a modified replication coding sequence. Also disclosed herein are vectors and cells comprising the nucleic acid molecule, which in turn comprises an artificial intron and a modified replication coding sequence.

[0004] Sequence Listing

[0005] This application contains a sequence listing submitted herewith as an xml file (name: "JBI6718-sequence-listing-ST26.xml", size: 37,181 bytes; created: March 24, 2023). The entire text of the sequence listing is incorporated by reference. Background Art

[0006] Adeno-associated virus (AAV) can be used to produce recombinant AAV particles containing DNA sequences of interest for delivery to target cells. These AAV particles lack viral genes, so the viral structure and packaging genes are provided in separate packaging plasmids. Typically, packaging plasmids contain replication (rep) genes and capsid (cap) viral genes. Summary of the invention

[0007] A plasmid for packaging recombinant adeno-associated virus serotype 5 (AAV5) viruses has been constructed. This plasmid contains the AAV replication genes from AAV2 and the capsid genes from AAV5. To prevent abnormal packaging of the rep and cap genes into the rAAV capsid, an artificial intron has been inserted into the rep gene. This 2 kb intron makes the rep and cap coding regions of the plasmid too large to be packaged.

[0008] Described herein are nucleic acid molecules comprising the nucleic acid sequence shown in SEQ ID NO: 1. Also described herein are nucleic acid molecules comprising the nucleic acid sequence shown in SEQ ID NO: 6.

[0009] Also described are vectors comprising a nucleic acid molecule comprising the nucleic acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 6. In certain embodiments, the vector comprises at least one of: a nucleic acid molecule comprising the nucleic acid sequence shown in SEQ ID NO: 6, a nucleic acid molecule comprising the nucleic acid sequence shown in SEQ ID NO: 7, and a nucleic acid molecule comprising the nucleic acid sequence shown in SEQ ID NO: 8.

[0010] In additional embodiments, the vector comprises a kanamycin resistance gene.

[0011] Also described herein is a vector comprising the nucleic acid sequence shown in SEQ ID NO:5.

[0012] Also described herein are cells transformed to express a nucleic acid molecule comprising the nucleic acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 6. In certain embodiments, the cell is transformed to express a vector comprising a nucleic acid molecule comprising the nucleic acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 6. In certain embodiments, the cell is transformed to express a vector comprising at least one of: a nucleic acid molecule comprising the nucleic acid sequence shown in SEQ ID NO: 6, a nucleic acid molecule comprising the nucleic acid sequence shown in SEQ ID NO: 7, and a nucleic acid molecule comprising the nucleic acid sequence shown in SEQ ID NO: 8.

[0013] Also described herein are cells transformed to express a vector comprising a nucleic acid molecule comprising the nucleic acid sequence set forth in SEQ ID NO: 5. In certain embodiments, the cell is a virus production cell.

[0014] Also described herein is a method for producing an adeno-associated virus packaging vector, the method comprising introducing the nucleic acid molecule according to claim 1 into a replication coding sequence to produce an intron-modified replication gene; and introducing the intron-modified replication gene into a vector backbone. DETAILED DESCRIPTION

[0015] The disclosed nucleic acid molecules, vectors and cells can be more easily understood by reference to the following detailed description, which forms a part of the present disclosure. It should be understood that the nucleic acid molecules, vectors and cells disclosed in the present invention are not limited to those nucleic acid molecules, vectors and cells specifically described and / or shown herein, and the terms used herein are only used to describe specific embodiments by way of example, and are not intended to limit the nucleic acid molecules, vectors and cells protected by the claims.

[0016] Unless specifically stated otherwise, any description of possible mechanisms or modes of action or reasons for improvement is intended for exemplary purposes only, and the nucleic acid molecules, vectors and cells disclosed herein are not bound by the correctness or incorrectness of any such suggested mechanisms or modes of action or reasons for improvement.

[0017] When enumerating or establishing a numerical range herein, the range includes its end values ​​and all individual integers and fractions within the range, and also includes each of the narrower ranges formed by all various possible combinations of those end values ​​and internal integers and fractions, to form a subset of the larger numerical group within the range to the same extent, as if each of those narrower ranges were explicitly enumerated. When stating a numerical range greater than a specified value herein, the range is however limited, and its upper limit is limited by a value operable in the context of the present invention as described herein. When stating a numerical range less than a specified value herein, the lower limit of the range is however limited by a non-zero value. It is not intended that the scope of the present invention is limited to the specific values ​​listed when the range is limited. All ranges include end values ​​and can be combined.

[0018] When "about" is used above to express a value as an approximation, it should be understood that the specific value constitutes another embodiment. A reference to a specific value includes at least that specific value unless the context clearly dictates otherwise.

[0019] It should be understood that certain features of the present invention are described in the context of separate embodiments for the sake of clarity, but may also be provided in combination in a single embodiment. That is, unless clearly incompatible or explicitly excluded, each individual embodiment is considered to be combinable with any other embodiment, and such combination is considered to be another embodiment. Conversely, various features of the present invention are described in the context of a single embodiment for the sake of simplicity, and may also be provided separately or in any sub-combination. Finally, although an embodiment may be described as part of a series of steps or part of a more general structure, each of the steps itself may also be considered an independent embodiment that can be combined with other embodiments.

[0020] Various terms related to various aspects of the specification are used throughout the specification and claims. Unless otherwise indicated, such terms are given the ordinary meaning of the art. Other specifically defined terms should be understood in a manner consistent with the definitions provided herein.

[0021] The term “comprising” is intended to include examples encompassed by the terms “consisting essentially of” and “consisting of; similarly, the term “consisting essentially of is intended to include examples encompassed by the term “consisting of.

[0022] When the descriptor "about" is used to represent a value as an approximation, it should be understood that the specific value constitutes another embodiment. Generally speaking, the use of the term "about" represents approximations that can vary depending on the desired properties that the subject matter disclosed in the present invention attempts to obtain, and will be interpreted based on its function in the specific context in which the approximation is used. Those skilled in the art will be able to interpret these approximations routinely. In some cases, the number of significant figures used for a particular value can be a non-limiting method for determining the scope of the word "about". In other cases, the gradient used in a range of values ​​can be used to determine the expected range that can be used for the term "about" for each value.

[0023] If not otherwise indicated, the term "about" means a variation of ±10% of the associated value. Thus, the term "about" is used to encompass variations of ±10% or less, ±5% or less, ±1% or less, ±0.5% or less, or ±0.1% or less from the specified value.

[0024] When a list is provided, it is understood that each individual element in the list and each combination of the list is a separate embodiment unless otherwise indicated. For example, a list of embodiments provided as "A, B, or C" will be considered to include embodiments "A," "B," "C," "A or B," "A or C," "B or C," or "A, B, or C."

[0025] As used herein, the singular forms "a," "an," and "the" include plural forms.

[0026] Nucleic acid molecules

[0027] Disclosed herein are nucleic acid molecules encoding artificial introns, which can be, for example, inserted into coding sequences such as AAV replication (rep) coding sequences. In certain embodiments, the nucleic acid molecule encodes an artificial intron comprising SEQ ID NO: 1. In certain embodiments, the nucleic acid molecule encodes an artificial intron, which is a complex of a 5' intron fragment from human β-actin (e.g., a nucleic acid sequence comprising SEQ ID NO: 2), a synthetic random non-coding sequence (e.g., a nucleic acid sequence comprising SEQ ID NO: 3), and a 3' intron fragment of human β-actin (e.g., a nucleic acid sequence comprising SEQ ID NO: 4). In certain embodiments, the length of the synthetic random non-coding sequence is about 2.1 kb. In certain embodiments, the synthetic random non-coding sequence is generated by a random sequence generator.

[0028] Described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) the nucleic acid sequence shown in SEQ ID NO: 1. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) an artificial nucleic acid sequence having at least 80% identity to the nucleic acid sequence shown in SEQ ID NO: 1. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) an artificial nucleic acid sequence having at least 85% identity to the nucleic acid sequence shown in SEQ ID NO: 1. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) an artificial nucleic acid sequence having at least 90% identity to the nucleic acid sequence shown in SEQ ID NO: 1. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) an artificial nucleic acid sequence having at least 95% identity to the nucleic acid sequence shown in SEQ ID NO: 1. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) an artificial nucleic acid sequence having at least 96% identity to the nucleic acid sequence shown in SEQ ID NO: 1. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) an artificial nucleic acid sequence that is at least 97% identical to the nucleic acid sequence shown in SEQ ID NO: 1. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) an artificial nucleic acid sequence that is at least 98% identical to the nucleic acid sequence shown in SEQ ID NO: 1. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) an artificial nucleic acid sequence that is at least 99% identical to the nucleic acid sequence shown in SEQ ID NO: 1.

[0029] As used herein, the term "artificial" refers to a nucleic acid molecule that has been modified by the hand of man, eg, does not occur in nature.

[0030] Described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) the nucleic acid sequence shown in SEQ ID NO:3. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) an artificial nucleic acid sequence having at least 80% identity to the nucleic acid sequence shown in SEQ ID NO:3. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) an artificial nucleic acid sequence having at least 85% identity to the nucleic acid sequence shown in SEQ ID NO:3. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) an artificial nucleic acid sequence having at least 90% identity to the nucleic acid sequence shown in SEQ ID NO:3. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) an artificial nucleic acid sequence having at least 95% identity to the nucleic acid sequence shown in SEQ ID NO:1. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) an artificial nucleic acid sequence having at least 96% identity to the nucleic acid sequence shown in SEQ ID NO:1. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) an artificial nucleic acid sequence that is at least 97% identical to the nucleic acid sequence shown in SEQ ID NO: 1. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) an artificial nucleic acid sequence that is at least 98% identical to the nucleic acid sequence shown in SEQ ID NO: 1. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) an artificial nucleic acid sequence that is at least 99% identical to the nucleic acid sequence shown in SEQ ID NO: 3.

[0031] Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) the nucleic acid sequence shown in SEQ ID NO: 2, the nucleic acid shown in SEQ ID NO: 3, and the nucleic acid shown in SEQ ID NO: 4. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) a nucleic acid sequence at least 95% identical to the nucleic acid sequence shown in SEQ ID NO: 2, a nucleic acid sequence at least 80%, at least 85%, at least 90%, or at least 95% identical to the nucleic acid sequence shown in SEQ ID NO: 3, and a nucleic acid sequence at least 95% identical to the nucleic acid sequence shown in SEQ ID NO: 4. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) a nucleic acid sequence at least 95% identical to the nucleic acid sequence shown in SEQ ID NO: 2, a nucleic acid sequence at least 95% identical to the nucleic acid sequence shown in SEQ ID NO: 3, and a nucleic acid sequence at least 95% identical to the nucleic acid sequence shown in SEQ ID NO: 4. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) a nucleic acid sequence having at least 96% identity to the nucleic acid sequence shown in SEQ ID NO: 2, a nucleic acid sequence having at least 96% identity to the nucleic acid sequence shown in SEQ ID NO: 3, and a nucleic acid sequence having at least 96% identity to the nucleic acid sequence shown in SEQ ID NO: 4. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) a nucleic acid sequence having at least 97% identity to the nucleic acid sequence shown in SEQ ID NO: 2, a nucleic acid sequence having at least 97% identity to the nucleic acid sequence shown in SEQ ID NO: 3, and a nucleic acid sequence having at least 97% identity to the nucleic acid sequence shown in SEQ ID NO: 4. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) a nucleic acid sequence having at least 98% identity to the nucleic acid sequence shown in SEQ ID NO: 2, a nucleic acid sequence having at least 98% identity to the nucleic acid sequence shown in SEQ ID NO: 3, and a nucleic acid sequence having at least 98% identity to the nucleic acid sequence shown in SEQ ID NO: 4. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) a nucleic acid sequence that is at least 99% identical to the nucleic acid sequence shown in SEQ ID NO:2, a nucleic acid sequence that is at least 99% identical to the nucleic acid sequence shown in SEQ ID NO:3, and a nucleic acid sequence that is at least 99% identical to the nucleic acid sequence shown in SEQ ID NO:4.In certain embodiments, the nucleic acid sequence shown in SEQ ID NO:2, the nucleic acid shown in SEQ ID NO:3, and the nucleic acid shown in SEQ ID NO:4 are operably linked.

[0032] Also disclosed herein are nucleic acid molecules encoding an intron-modified AAV rep coding sequence comprising an artificial intron. In certain embodiments, the nucleic acid molecule encoding the intron-modified AAV rep coding sequence comprises SEQ ID NO:6. In certain embodiments, the nucleic acid molecule encoding the artificial intron comprises SEQ ID NO:1. In certain embodiments, the artificial intron is inserted into a CAGG sequence in the replication coding sequence. In certain embodiments, the artificial intron is inserted into the CAGG sequence of the AAV rep coding sequence before the last "G." In certain embodiments, the insertion of the artificial intron does not disrupt the translation of the AAV rep coding sequence.

[0033] Described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) the nucleic acid sequence shown in SEQ ID NO:6. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) a nucleic acid sequence that is at least 95% identical to the nucleic acid sequence shown in SEQ ID NO:6. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) a nucleic acid sequence that is at least 96% identical to the nucleic acid sequence shown in SEQ ID NO:6. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) a nucleic acid sequence that is at least 97% identical to the nucleic acid sequence shown in SEQ ID NO:6. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) a nucleic acid sequence that is at least 98% identical to the nucleic acid sequence shown in SEQ ID NO:6. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) a nucleic acid sequence that is at least 99% identical to the nucleic acid sequence shown in SEQ ID NO:6.

[0034] Also disclosed herein are nucleic acid molecules encoding an intron-modified AAV rep coding sequence, a VP1 coding sequence, and a poly(A) signal. In certain embodiments, the nucleic acid molecule encoding the intron-modified AAV rep coding sequence comprises SEQ ID NO: 6. In certain embodiments, the nucleic acid molecule encoding the VP1 coding sequence comprises SEQ ID NO: 7. In certain embodiments, the nucleic acid molecule encoding the poly(A) signal comprises SEQ ID NO: 7.

[0035] In certain embodiments, the VP1 coding sequence is an AAV5 (adeno-associated virus type 5) VP1 coding sequence. In certain embodiments, the poly(A) signal is an AAV2 (adeno-associated virus type 2) poly(A) signal.

[0036] Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) the nucleic acid sequence shown in SEQ ID NO: 6, the nucleic acid shown in SEQ ID NO: 7, and the nucleic acid shown in SEQ ID NO: 8. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) a nucleic acid sequence at least 80% identical to the nucleic acid sequence shown in SEQ ID NO: 6, a nucleic acid sequence at least 80% identical to the nucleic acid sequence shown in SEQ ID NO: 7, and a nucleic acid sequence at least 80% identical to the nucleic acid sequence shown in SEQ ID NO: 8. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) a nucleic acid sequence at least 85% identical to the nucleic acid sequence shown in SEQ ID NO: 6, a nucleic acid sequence at least 85% identical to the nucleic acid sequence shown in SEQ ID NO: 7, and a nucleic acid sequence at least 85% identical to the nucleic acid sequence shown in SEQ ID NO: 8. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) a nucleic acid sequence having at least 90% identity to the nucleic acid sequence shown in SEQ ID NO: 6, a nucleic acid sequence having at least 90% identity to the nucleic acid sequence shown in SEQ ID NO: 7, and a nucleic acid sequence having at least 90% identity to the nucleic acid sequence shown in SEQ ID NO: 8. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) a nucleic acid sequence having at least 95% identity to the nucleic acid sequence shown in SEQ ID NO: 6, a nucleic acid sequence having at least 95% identity to the nucleic acid sequence shown in SEQ ID NO: 7, and a nucleic acid sequence having at least 95% identity to the nucleic acid sequence shown in SEQ ID NO: 8. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) a nucleic acid sequence having at least 96% identity to the nucleic acid sequence shown in SEQ ID NO: 6, a nucleic acid sequence having at least 96% identity to the nucleic acid sequence shown in SEQ ID NO: 7, and a nucleic acid sequence having at least 96% identity to the nucleic acid sequence shown in SEQ ID NO: 8. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) a nucleic acid sequence that is at least 97% identical to the nucleic acid sequence shown in SEQ ID NO:6, a nucleic acid sequence that is at least 97% identical to the nucleic acid sequence shown in SEQ ID NO:7, and a nucleic acid sequence that is at least 97% identical to the nucleic acid sequence shown in SEQ ID NO:8.Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) a nucleic acid sequence having at least 98% identity to the nucleic acid sequence shown in SEQ ID NO: 6, a nucleic acid sequence having at least 98% identity to the nucleic acid sequence shown in SEQ ID NO: 7, and a nucleic acid sequence having at least 98% identity to the nucleic acid sequence shown in SEQ ID NO: 8. Also described herein are nucleic acid molecules comprising (or consisting of or consisting essentially of) a nucleic acid sequence having at least 99% identity to the nucleic acid sequence shown in SEQ ID NO: 6, a nucleic acid sequence having at least 99% identity to the nucleic acid sequence shown in SEQ ID NO: 7, and a nucleic acid sequence having at least 99% identity to the nucleic acid sequence shown in SEQ ID NO: 8. In certain embodiments, the nucleic acid sequence shown in SEQ ID NO: 6, the nucleic acid shown in SEQ ID NO: 7, and the nucleic acid shown in SEQ ID NO: 8 are operably linked.

[0037] The terms "identical" or "percent identity" in the context of two or more nucleic acids refers to two or more sequences or subsequences that are the same or have a specified percentage of nucleotides that are the same when compared and aligned for maximum correspondence, as measured using one of the following sequence comparison algorithms or by visual inspection.

[0038] For sequence comparison, usually one sequence is used as a reference sequence to which a test sequence is compared. When a sequence comparison algorithm is used, the test sequence and the reference sequence are input into a computer, subsequence coordinates are specified (if necessary), and program parameters for the sequence algorithm are specified. Then, the sequence comparison algorithm calculates the sequence identity percentage for the test sequence relative to the reference sequence based on the specified program parameters.

[0039] Optimal alignment of sequences for comparison can be performed, for example, by the local homology algorithm of Smith and Waterman (Adv. Appl. Math. 2:482 (1981)), by the homology alignment algorithm of Needleman and Wunsch (J Mol. Biol., 48:443 (1970)), by searching the similarity method of Pearson and Lipman (Proc. Nat'l. Acad. Sci. USA 85:2444 (1988)), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Computer Group, 575 Science Dr., Madison, WI), or by visual inspection (see generally, Current Protocols in Molecular Biology, FM Ausubel et al., eds., Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., (1995 Supplement) (Ausubel)).

[0040] Examples of algorithms suitable for determining percentages of sequence identity and sequence similarity are BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., (1990) J. Mol. Biol., 215: 403-410 and Altschul et al., (1997) Nucleic Acids Res. 25: 3389-3402, respectively. Software for performing BLAST analysis is publicly available through the National Center for Biotechnology Information. The algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence that match or satisfy some positive threshold score T when aligned with words of the same length in the database sequence. T is referred to as the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits serve as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence as far as the cumulative alignment score can be increased.

[0041] For nucleotide sequences, cumulative scores are calculated using the parameters M (reward score for a pair of matching residues; always > 0) and N (penalty score for mismatched residues; always < 0). For amino acid sequences, a scoring matrix is ​​used to calculate the cumulative score. Extension of the word hits in each direction stops when: the cumulative alignment score drops by the amount X from its maximum achieved value; the cumulative score becomes zero or lower due to the accumulation of one or more negative score residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses a word length (W) of 11, an expectation (E) of 10, M = 5, N = -4, and a comparison of both chains by default. For amino acid sequences, the BLASTP program uses a word length (W) of 3, an expectation (E) of 10, and a BLOSUM62 scoring matrix by default (see Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89: 10915 (1989)).

[0042] In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability that a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of a test nucleic acid to a reference nucleic acid is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

[0043] Another indication that two nucleic acid sequences are substantially identical is that the polypeptide encoded by the first nucleic acid immunologically cross-reacts with the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, e.g., where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules hybridize to each other under stringent conditions.

[0044] In some embodiments, the nucleic acid molecule comprises DNA.

[0045] In some embodiments, the nucleic acid molecule comprises RNA.

[0046] In some embodiments, the RNA is mRNA.

[0047] In some embodiments, the nucleic acid molecule comprises a promoter, an enhancer, a polyadenylation site, a Kozak sequence, a stop codon, or any combination thereof.

[0048] Methods for producing nucleic acid molecules of the present disclosure are known in the art and include chemical synthesis, enzymatic synthesis (e.g., in vitro transcription), enzymatic or chemical cleavage of longer precursors, chemical synthesis of smaller fragments of polynucleotides followed by ligation of these fragments, or known PCR methods. The polynucleotide sequence to be synthesized can be designed with appropriate codons for the desired amino acid sequence. In general, preferred codons can be selected for the intended host in which the sequence will be used for expression.

[0049] Carrier

[0050] The present disclosure also provides a vector comprising, consisting of, or consisting essentially of any of the nucleic acid molecules disclosed herein. The present disclosure also provides a vector comprising a nucleic acid molecule encoding any of the polypeptides disclosed herein.

[0051] The vector disclosed herein can be a packaging vector containing the AAV coding region (AAV rep and cap genes) but without the 145bp inverted terminal repeats (ITRs). The packaging vector disclosed in the present invention is in a suitable cell line (e.g., human 293 cells) with the DNA contained in the AAV ITR chimeric protein encoding construct. The cells can then be infected with adenovirus. Viral vectors (sometimes also referred to as viral particles) can be purified from cell lysates using methods known in the art (e.g., such as cesium chloride density gradient ultracentrifugation) and verified to ensure that they do not contain detectable replication-competent AAV or adenovirus (e.g., by cytopathic effect bioassay).

[0052] Described herein are vectors comprising a nucleic acid molecule comprising the nucleic acid sequence shown in SEQ ID NO: 1. Also described herein are vectors comprising a nucleic acid molecule comprising a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the nucleic acid sequence shown in SEQ ID NO: 1.

[0053] Also described herein are vectors comprising a nucleic acid molecule comprising the nucleic acid sequence shown in SEQ ID NO: 6. Also described herein are vectors comprising a nucleic acid molecule comprising a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the nucleic acid sequence shown in SEQ ID NO: 6.

[0054] In certain embodiments, the vector comprises the following: a nucleic acid molecule comprising the nucleic acid sequence shown in SEQ ID NO: 6, a nucleic acid molecule comprising the nucleic acid sequence shown in SEQ ID NO: 7, and a nucleic acid molecule comprising the nucleic acid sequence shown in SEQ ID NO: 8. Also described herein are vectors comprising the following: a nucleic acid molecule comprising a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the nucleic acid sequence shown in SEQ ID NO: 6, a nucleic acid molecule comprising a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the nucleic acid sequence shown in SEQ ID NO: 7, and a nucleic acid molecule comprising a nucleic acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the nucleic acid sequence shown in SEQ ID NO: 8. In certain embodiments, the nucleic acid sequence shown in SEQ ID NO:6, a nucleic acid molecule comprising SEQ ID NO:7, and a nucleic acid molecule comprising SEQ ID NO:8 are operably linked.

[0055] In additional embodiments, the vector comprises (or consists of or consists essentially of) a nucleic acid molecule comprising (or consists of or consists essentially of) the nucleic acid sequence shown in SEQ ID NO:5. In certain embodiments, the vector comprises a nucleic acid sequence having at least 80% identity to the nucleic acid sequence shown in SEQ ID NO:5. In certain embodiments, the vector comprises a nucleic acid sequence having at least 85% identity to the nucleic acid sequence shown in SEQ ID NO:5. In certain embodiments, the vector comprises a nucleic acid sequence having at least 90% identity to the nucleic acid sequence shown in SEQ ID NO:5. In certain embodiments, the vector comprises a nucleic acid sequence having at least 95% identity to the nucleic acid sequence shown in SEQ ID NO:5. In certain embodiments, the vector comprises a nucleic acid sequence having at least 96% identity to the nucleic acid sequence shown in SEQ ID NO:5. In certain embodiments, the vector comprises a nucleic acid sequence having at least 97% identity to the nucleic acid sequence shown in SEQ ID NO:5. In certain embodiments, the vector comprises a nucleotide sequence having at least 98% identity to the nucleic acid sequence shown in SEQ ID NO:5. In certain embodiments, the vector comprises a nucleic acid sequence that is at least 99% identical to the nucleic acid sequence shown in SEQ ID NO:5.

[0056] The vector can be a vector intended for expressing the polynucleotide of the present disclosure in any host, such as bacteria, yeast or mammals. Suitable expression vectors can be replicated in host organisms as episomes or as an integral part of the host chromosome DNA. Usually, the expression vector comprises a selective marker, such as ampicillin resistance, hygromycin resistance, tetracycline resistance, kanamycin resistance or neomycin resistance, to allow detection of those cells transformed or transduced with the desired DNA sequence. In certain embodiments, the vector comprises a kanamycin resistance gene.

[0057] Exemplary vectors are plasmids, cosmids, phages, viral vectors or artificial chromosomes.

[0058] Suitable vectors that can be used include, but are not limited to, bacterial: pUC57, pBs, phagescript, PsiX174, pBluescript SK, pBs KS, pNH8a, pNH16a, pNH18a, pNH46a (Stratagene, La Jolla, Calif., USA), pTrc99A, pKK223-3, pKK233-3, pDR540, and pRIT5 (Pharmacia, Uppsala, Sweden). Eukaryotic vectors: pWLneo, pSV2cat, pOG44, PXR1, pSG (Stratagene), pSVK3, pBPV, pMSG, and pSVL (Pharmacia). In certain embodiments, the vector is pUC57.

[0059] The present disclosure provides an expression vector comprising a nucleic acid molecule of the present disclosure. The present disclosure also provides an expression vector comprising a nucleic acid molecule encoding a polypeptide of the present disclosure.

[0060] The present invention also describes a method for producing an adeno-associated virus (AAV) packaging vector, the method comprising: (a) introducing a nucleic acid molecule comprising the nucleic acid sequence shown in SEQ ID NO:1 into an AAV replication coding sequence to produce an intron-modified AAV replication gene; and (b) introducing the intron-modified AAV replication gene into a vector backbone.

[0061] Engineered cells expressing nucleic acids of the present disclosure

[0062] Engineered cells expressing the nucleic acid molecules or vectors of the present disclosure are within the scope of the present disclosure.

[0063] Suitable engineered cells include those obtained from, for example, animals and humans.In certain embodiments, the cell is a virus production cell.

[0064] In certain embodiments, described herein are cells transformed to express a nucleic acid molecule comprising the nucleic acid sequence shown in SEQ ID NO: 1. In certain embodiments, described herein are cells transformed to express a nucleic acid molecule comprising the nucleic acid sequence shown in SEQ ID NO: 6.

[0065] In certain embodiments, described herein are cells transformed to express a vector comprising a nucleic acid molecule comprising the nucleic acid sequence shown in SEQ ID NO:6, a nucleic acid molecule comprising SEQ ID NO:7, and a nucleic acid molecule comprising SEQ ID NO:8.

[0066] In certain embodiments, described herein are cells transformed to express a vector comprising a nucleic acid molecule comprising SEQ ID NO:5.

[0067] Example

[0068] This example is provided for illustrative purposes only, and is not intended to limit the scope of the claims provided herein.

[0069] Example 1. AAV5 RepCap Plasmid

[0070] Engineering introns into the AAV2 Rep gene

[0071] The artificial intron used to disrupt the REP coding sequence (SEQ ID NO: 1) is a complex of a 5' intron fragment from human β-actin (SEQ ID NO: 2), a 2.1 kb synthetic random non-coding sequence (SEQ ID NO: 3), and a 3' intron fragment from human β-actin (SEQ ID NO: 4). SEQ ID NO: 2 is based on a fragment generated by a random sequence generator (https: / / birc.au.dk / ~palle / php / fabox / random_sequence_generator.php), which was subsequently modified to remove potential splicing signals.

[0072] Although the AAV Rep gene utilizes alternative splicing to produce several different protein isoforms, there are no pre-existing introns that are always spliced ​​out of all protein-coding transcripts. Therefore, it is not possible to simply increase the size of existing introns. Since the recognition of splice donors or splice acceptors also depends on the flanking exon sequences, there are only specific positions in the REP gene where the insertion of an intron will result in efficient RNA splicing.

[0073] To identify a suitable intron insertion site, the "CAGG" sequence of the REP gene was scanned, and a composite test sequence was generated in which the intron (SEQ ID NO: 1) was inserted before the last G. These composite sequences were subjected to splice site prediction analysis using the NETGene2 algorithm (https: / / services.healthtech.dtu.dk / service.php?NetGene2-2.42). The insertion site used in the final construct appears in a portion of the Rep coding sequence that is common to all four REP protein isoforms (Rep78, Rep68, Rep50, Rep40). Another potential splice donor site was predicted by NetGene2 upstream of the intron insertion; this site was mutated from GT to AT at position 800 of SEQ ID NO: 5 to make splicing at the inserted intron more efficient.

[0074] Plasmid P849 (SEQ ID NO: 5) was generated by gene synthesis. It contains the intron-modified AAV2 REP gene (SEQ ID NO: 6), the AAV5 VP1 coding sequence (SEQ ID NO: 7), the AAV2 polyadenylation signal (SEQ ID NO: 8) cloned into a plasmid backbone derived from pUC57-KAN containing the kanamycin resistance gene. A variant of this plasmid was generated in which the AAV5 VP1 sequence (SEQ ID NO: 10) was deleted; this plasmid can be used to generate plasmids for packaging additional serotypes by cloning in the VP1 coding region from other AAVs.

[0075] Testing plasmids in AAV packaging assays

[0076] Material

[0077] Cell culture : Virus producer cells (VPC) (Thermo-Fisher, Waltham, MA, #A35347); DMEM (Thermo-Fisher, #11995-040); Fetal bovine serum (FBS) (Cytiva Life Sciences, Marlborough, MA; #SH30079.03IR); Opti-MEM (Thermo-Fisher, #31985-062).

[0078] Chemicals, Buffers and Enzymes: 1M Tris, pH 7.5 (Millipore-Sigma, St. Louis, MO, #T2319-1L); 1M magnesium chloride (Millipore-Sigma, #63069-500ML); Triton-X100 (Millipore-Sigma, T9284-100ML); AAV lysis buffer (10mM Tris-HCl, pH 7.5; 20mM MgCl2, 1% Triton-X100 (v / v)); 10% Pluronic F-68 (Thermo-Fisher, #24040-032); 10x GeneAmp PCR buffer I, containing 1.5mM MgCl2 (Thermo-Fisher, #4379876); sheared salmon sperm DNA (Thermo-Fisher, #AM9680); virus dilution buffer (VDB) (1x PCR buffer I, 2 μg / ml sheared salmon sperm DNA, and 0.05% Pluronic F-68); benzonatate nuclease 250 units / μl (Millipore-Sigma E1014-25K); PEI-MAX transfection reagent, dissolved in water at 1 mg / ml, pH 7.5 (Polysciences, Warrington PA, #24765-2).

[0079] Digital Droplet PCR : 2x SuperMix for probes (Bio-Rad, Hercules, California, #186-3026); DG32 AutoDG cartridge (Bio-Rad, #1864108); automatic droplet generator oil in PBS (Bio-Rad, #1864110); droplet reader oil (Bio-Rad, #1863004); automatic droplet generator (Bio-Rad catalog, #186-4101); QX200 droplet reader (Bio-Rad, #186-4003); C1000 contact thermal cycler with deep well reaction module (Bio-Rad, #185-1197).

[0080] PrimeTime qPCR assay : 20x stocks for these assays consisted of forward and reverse PCR primers (18 μM), 5' nuclease probe containing fluorescence quenchers ZEN and Black Hole Quencher 1 (3IABkFQ), and FAM or HEX fluorescent reporter dyes (5 μM). Assays were synthesized by Integrated DNA Technologies, Inc., Coralville IA.

[0081] Determination

[0082] VPC cells were seeded in 5 ml growth medium (DMEM + 10% FBS) at 5E6 cells / T25 flask and incubated in a CO2 incubator for 2 days at 37°C. 4.2 μg P849 + 6.8 μg adenovirus helper plasmid + 2.6 μg Cis plasmid (mCherry-IRES-FLuC transgene flanked by AAV2 ITR) was diluted to 80 μl with Opti-MEM, mixed with 80 μl PEI-MAX (diluted to 212.5 μg / ml in OptiMEM), and incubated at room temperature for 30 minutes. The transfection mixture was added to 12 ml culture medium (DMEM + 0.5% FBS) and used to replace the growth medium in the T25 flask. The cells were incubated in a CO2 incubator at 37°C for 72 hours. The cells and medium were transferred to a 125 ml conical flask containing 1.2 ml lysis buffer plus 160 units of benzonatate, and the flask was shaken at 120 rpm in a CO2 incubator at 37°C for one hour. The lysed cells were clarified by centrifugation at 4000 rpm for 15 minutes, and the supernatant was transferred to a new tube.

[0083] AAV titers were measured by digital droplet PCR (ddPCR). A 2 μl aliquot of the lysate was diluted into 18 μl of virus dilution buffer containing 0.2 units of benzonatate and incubated at room temperature for 30 minutes. The samples were further diluted into triplicates with virus dilution buffer, mixed with the ddPCR master mix, and ddPCR assays were performed on mCherry, and droplets were generated using a Bio-Rad automatic droplet generator. The droplets were subjected to PCR with a curve (95°C 10min; 42X (94°C 30s, 60°C 1min, 72°C 15s, all three cycle times were 2°C / s; 98°C 10 minutes), and droplets were detected using a QX200 droplet reader (Bio-Rad) according to the manufacturer's instructions.

[0084] result

[0085] A total of 1.2E+12±8.1E+10 AAV vector genomes were generated (DNAse-resistant particles detected by the mCherry probe), whereas the negative control sample without lysate produced no signal. These data indicate that P849 encodes the necessary AAVRep and Cap genes to package the mCherry transgene from the Cis plasmid into DNAse-resistant particles, consistent with the production of recombinant AAV. In addition, the introns inserted into REP do not appear to disrupt the function of these genes.

[0086] It will be appreciated by those skilled in the art that modifications may be made to the above embodiments without departing from the broad inventive concept of the present invention. Therefore, it should be understood that the present invention is not limited to the specific embodiments disclosed herein, but is intended to cover modifications within the spirit and scope of the present invention as defined in this specification.

[0087] sequence

[0088]

[0089]

[0090]

[0091]

[0092]

[0093]

[0094]

[0095]

[0096]

[0097]

[0098]

[0099]

[0100]

[0101]

[0102]

Claims

1. A nucleic acid molecule comprising a nucleic acid sequence that is at least 95% identical to SEQ ID NO:

1.

2. A nucleic acid molecule comprising a nucleic acid sequence that is at least 95% identical to SEQ ID NO:

6.

3. A vector comprising the nucleic acid molecule according to claim 1 or claim 2.

4. The vector of claim 3, wherein the vector comprises: the nucleic acid molecule of claim 2, a nucleic acid molecule comprising a nucleic acid sequence at least 95% identical to SEQ ID NO:7, and a nucleic acid molecule comprising a nucleic acid sequence at least 95% identical to SEQ ID NO:

8. The vector according to claim 4 , wherein the vector comprises a kanamycin resistance gene.

6. The vector of claim 3, wherein the vector comprises a nucleic acid molecule comprising a nucleic acid sequence that is at least 95% identical to SEQ ID NO:

5.

7. A vector comprising a nucleic acid sequence that is at least 95% identical to SEQ ID NO:

5.

8. A cell transformed to express a nucleic acid molecule according to claim 1 or 2 or a vector according to any one of claims 4 to 7.

9. The cell according to claim 8, wherein the cell is a virus producing cell.

10. A method for producing an adeno-associated virus packaging vector, the method include: (a) introducing the nucleic acid molecule according to claim 1 into a replication coding sequence to produce an intron-modified replicator; as well as (b) introducing the intron-modified replicative gene into a vector backbone.

11. A nucleic acid molecule comprising a nucleic acid sequence that is at least 95% identical to SEQ ID NO: 10.